Navigation

Colorectal cancer (metastatic) - bevacizumab

Bevacizumab in combination with oxaliplatin and either 5-fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer

Status: History
Expected date of issue: December 2010
Referral date: November 2008
Process: STA
Topic area:
  • Cancer
  • Digestive system
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Panagiota Vrouchou
Communications manager: Alice Law
Project manager: Kate Moore
Assessment Group / Evidence Review Group: NHS Centre for Reviews & Dissemination and Centre for Health Economics, York
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 23 July 2009
1st appraisal committee meeting: 27 October 2009
2nd appraisal committee meeting 25 March 2010
3rd appraisal committee meeting: 27 October 2010
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Roche Products (bevacizumab)

Patient/carer groups

  • Beating Bowel Cancer
  • Bowel Cancer UK
  • Macmillan Cancer Support

Professional groups

  • Association of Surgeons of Great Britain and Ireland
  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Physicians, Medical Oncology Joint Special Committee

Others

  • Department of Health
  • NHS Manchester
  • Welsh Assembly Government

General

  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Medicines and Healthcare products Regulatory Agency
  • NHS Quality Improvement Scotland

Comparator manufacturer(s)

  • Hospira (calcium folinate, fluorouracil, oxaliplatin)
  • Medac UK(disodium folinate, fluorouracil, oxaliplatin)
  • Merck Serono (tegafur with uracil)
  • Pfizer (irinotecan)
  • Roche Products (capecitabine)
  • Sanofi-Aventis (oxaliplatin)

Relevant research groups

  • Institute of Cancer Research
  • MRC Clinical Trials Unit

Evidence Review Group

  • National Institute for Health Research Health Technology Assessment Programme
  • School of Health and Related Research (ScHARR)

Associated Guideline Groups

  • National Collaborating Centre for Cancer

Associated Public Health Groups

  • None

Top


 

Project history

Date Update
25 January 2010 Please note that NICE has now been informed that the manufacturer for Bevacizumab (Roche) has proposed an amendment to the patient access scheme and this is currently subject to discussion between the manufacturer and the Department of Health. In order to allow for consideration of the impact of amendment to the patient access scheme on clinical and cost effectiveness, the Appraisal Committee will discuss this topic again at its meeting on 25 March 2010. Therefore the discussion scheduled for 27 January 2010 will not be taking place.
28 May 2010 The ACD for this topic cannot yet be released for consultation due to further issues raised by the manufacturer regarding confidentiality of information. We will let you know as soon as possible when we can proceed to ACD consultation and apologise that we cannot provide more clarity about the future timelines for this appraisal. Therefore this will not be discussed at the committee meeting on 23rd June 2010.
Top


 

Key documents

This page was last updated: 13 December 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.